<DOC>
	<DOCNO>NCT02698176</DOCNO>
	<brief_summary>This study determine recommend dose MK-8628 ( formerly know OTX015 ) study participant advance nuclear protein testis ( NUT ) midline carcinoma ( NMC ) , triple negative breast cancer ( TNBC ) , non-small cell lung cancer ( NSCLC ) , castration-resistant prostate cancer ( CRPC ) . This two-part parallel study : Part A establish recommend dose evaluate dose limit toxicity ( DLT ) , safety , discontinuation , early efficacy Part B enroll participant NMC evaluate safety efficacy population .</brief_summary>
	<brief_title>A Dose Exploration Study With MK-8628 Participants With Selected Advanced Solid Tumors ( MK-8628-006 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Males female ≥18 year age NSCLC , TNBC , CRPC Males females ≥16 year age NMC Diagnosis one follow advance solid tumor standard therapy either exist proven ineffective , intolerable inacceptable participant : NMC ; TNBC ; NSCLC ; CRPC Have least 1 measurable lesion per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 . CRPC participant may enrol objective evidence disease per Prostate Cancer Working Group ( PCWG2 ) criteria Life expectancy ≥3 month Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤1 Have interval ≥3 week ( ≥2 week NMC participant ) since chemotherapy ( ≥6 week nitrosoureas mitomycin C ) , immunotherapy , hormone therapy anticancer therapy surgical intervention resection , ≥3 halflives monoclonal antibody , ≥5 halflives noncytotoxic agent ( whichever longer ) CRPC participant must maintain ongoing androgen deprivation therapy gonadotropin release hormone ( GnRH ) analogue , antagonist orchiectomy provide serum testosterone &lt; 50 ng/dL ( &lt; 1.7 nmol/L ) Participants receive bisphosphonate denosumab therapy must stable dos least 4 week start study therapy Females must pregnant ( negative urine serum human chorionic gonadotropin test within 72 hour study start ) Females childbearing potential male participant must agree use adequate contraception start first dose trial treatment 90 day last dose study medication Has inability swallow oral medication presence gastrointestinal disorder ( e.g . malabsorption ) deem jeopardize intestinal absorption MK8628 Has persistent grade &gt; 1 clinically significant toxicity relate prior antineoplastic therapy ( except alopecia ) . Stable sensory neuropathy ≤ grade 2 National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Version 4.0 accept Known primary central nervous system ( CNS ) malignancy symptomatic untreated CNS metastasis . Treated stable CNS metastasis allow . History prior concomitant malignancy within 3 year study start Have serious illness medical condition , active infection , unresolved bowel obstruction , psychiatric disorder , cerebrovascular accident within 1 year study start Known human immunodeficiency virus ( HIV ) and/or active Hepatitis B C infection Have one follow cardiacrelated condition : Congestive heart failure angina pectoris ( except medically control ) ; myocardial infarction ( within 1 year study start ) ; uncontrolled hypertension ; uncontrolled arrhythmia Other concomitant anticancer treatment Participation another clinical trial treatment investigational drug ( exclude anticancer treatment ) within 30 day study start Concomitant therapy strong CYP3A4 inhibitor inducer Therapeutic anticoagulation ( e.g . warfarin , heparin , etc . ) must stop least 7 day prior first dose MK8628 . Lowdose low molecular weight heparin ( LMWH ) permit Is pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>OTX015</keyword>
	<keyword>MK-8628</keyword>
</DOC>